Past Projects – Lean Launchpad Singapore
Nus enterprise website

Past Projects

LIFE SCIENCES

  • 2016
    (6th run)
    EXOPLEX

    NUS Department of Pharmacy

    Principal Investigators: Assoc Prof. Giorgia Pastorin
    Team members: Goh Wei Jiang, Shui Zou

    EXOPLEX is a novel drug delivery system of nanoscale dimensions with features of improved cellular uptake, cell targeting and low toxicity, as well as the ability for further functionalisation. Currently we are using EXOPLEXs to transfect or introduce genetic material into difficult-to-transfect cell lines and evaluating its commercial viability as a research reagent. EXOPLEXs would be a one-step transfection reagent with the aim of improved transfection efficiency compared to conventional non-viral transfection methods.

  • 2016
    (6th run)
    Next Generation

    NUS Department of Food Science Technology

    Principal Investigators: Assoc Prof. Huang Dejian
    Team members: Liang Dong, Katja Krizman, Ivan Zwe, See Xin Yi, Jun Matsumoto

    Garlic supplements are known for their health promoting effects, especially cardiovascular protection. This is achieved through the generation of Hydrogen Sulfide (H2S), a gasotransmitter from garlic polysulfide. However, conventional polysulfides release H2S instantly within the human body, while slow-releasing H2S donor is preferred for longer lasting effects; they also have a strong garlic smell. We have developed a method to make a compound which is safe, water soluble, free of garlic smell, and more importantly, is able to generate H2S slowly.

  • 2016
    (6th run)
    Colon Patch

    Start-up

    Team members: Dr. Ajith Isaac, Dr. Gary Ang, Dr. Shawn Gao, Samarth Bhargava

    We are developing a biomedical device to be used in colorectal surgery to reduce the risk of leakage from the intestine (anastomotic leakage). Based on our pilot experiments, our proposed solution to this problem is comprised of a novel sealant and propriety delivery device that can be easily adopted into the current surgical workflow. The sealant will be delivered at the site of the anastomosis as a prophylactic to reduce leak rates.

  • 2016
    (6th run)
    LumineSense

    NUS Department of Bioengineering

    Principal Investigators: Prof. Zhang Yong
    Team members: Dr. Muthu Kumara, Akshaya Bansal, Chris Ho Jun Hui

    Upconversion nanoparticles are a unique range of fluorescent nanoparticles. These nanoparticles act as a platform technology and can be used in a variety of applications such as imaging, food testing, environmental testing, veterinary testing, in-vitro diagnostics, anti-counterfeiting, optogenetics and cancer therapy.

  • 2016
    (6th run)
    Wireless Monitoring Device

    NUS Department of Electrical and Computer Engineering

    Principal Investigators: Assoc Prof. Heng Chun Huat
    Team members: David Wong, Yu Ju Feng, Siddharth Manoharan

    We have designed a light-weight integrated wearable medical grade wireless vital signs patch for continuous acquisition of vital signs such as temperature, respiration, 3 lead-ECG, pulse oximeter and blood pressure to allow clinicians to have continuous healthcare surveillance on their patients. It is also supported by a cloud-based client application, that displays, records and analyses (trending and alerts) real-time vital stats to assist clinicians in providing better clinical care. This solution can also be realised in private clinics, home-care, community and rural healthcare monitoring.

  • 2016
    (6th run)
    Pharmacogenetics Algorithm

    NUS Department of Biochemistry

    Principal Investigators: Assoc Prof. Caroline Lee
    Team members: Dr. Maulana Bachtiar, Tony Sugiarta, Theodora Chung, Dr. Ang Siang Yun

    A new algorithm to predict drugs which may display population differences in response through the interrogation of the human genome and drug response pathways. The robustness of this strategy is evident from the accurate prediction of 10 of 11 drugs which were previously reported to show population differences in response. A high proportion of drugs with pharmacogenetics warning-labels are also predicted to show population differences in response.